Citadel Advisors’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.3M | Buy |
23,700
+4,400
| +23% | +$2.82M | ﹤0.01% | 2847 |
|
|
2025
Q4 | $13.1M | Sell |
19,300
-12,700
| -40% | -$8.65M | ﹤0.01% | 2889 |
|
|
2025
Q3 | $20.4M | Buy |
32,000
+4,700
| +17% | +$2.85M | ﹤0.01% | 2308 |
|
|
2025
Q2 | $14.6M | Buy |
27,300
+10,300
| +61% | +$4.93M | ﹤0.01% | 2544 |
|
|
2025
Q1 | $7.14M | Sell |
17,000
-12,200
| -42% | -$5.3M | ﹤0.01% | 3342 |
|
|
2024
Q4 | $12.1M | Sell |
29,200
-10,000
| -26% | -$4.39M | ﹤0.01% | 2741 |
|
|
2024
Q3 | $19.8M | Sell |
39,200
-9,600
| -20% | -$4.66M | ﹤0.01% | 2065 |
|
|
2024
Q2 | $23.8M | Buy |
48,800
+7,900
| +19% | +$3.97M | ﹤0.01% | 1825 |
|
|
2024
Q1 | $22.1M | Sell |
40,900
-4,900
| -11% | -$2.68M | ﹤0.01% | 1964 |
|
|
2023
Q4 | $25.4M | Buy |
45,800
+17,800
| +64% | +$8.36M | 0.01% | 1777 |
|
|
2023
Q3 | $12.2M | Buy |
28,000
+6,800
| +32% | +$3.39M | ﹤0.01% | 2427 |
|
|
2023
Q2 | $10.6M | Sell |
21,200
-73,600
| -78% | -$35.3M | ﹤0.01% | 2597 |
|
|
2023
Q1 | $47.4M | Buy |
94,800
+18,600
| +24% | +$8.9M | 0.01% | 1118 |
|
|
2022
Q4 | $31.1M | Sell |
76,200
-17,600
| -19% | -$6.83M | 0.01% | 1526 |
|
|
2022
Q3 | $30.6M | Buy |
93,800
+28,300
| +43% | +$10.4M | 0.01% | 1459 |
|
|
2022
Q2 | $23M | Buy |
65,500
+10,600
| +19% | +$4.32M | 0.01% | 1702 |
|
|
2022
Q1 | $30M | Buy |
54,900
+2,700
| +5% | +$1.42M | 0.01% | 1547 |
|
|
2021
Q4 | $34.4M | Sell |
52,200
-34,900
| -40% | -$21.9M | 0.01% | 1488 |
|
|
2021
Q3 | $54.2M | Buy |
87,100
+24,700
| +40% | +$16.6M | 0.01% | 1067 |
|
|
2021
Q2 | $39.4M | Buy |
62,400
+11,600
| +23% | +$6.41M | 0.01% | 1327 |
|
|
2021
Q1 | $24.9M | Buy |
50,800
+12,400
| +32% | +$6.21M | 0.01% | 1719 |
|
|
2020
Q4 | $19.2M | Buy |
38,400
+6,500
| +20% | +$2.91M | 0.01% | 1849 |
|
|
2020
Q3 | $12.5M | Sell |
31,900
-6,400
| -17% | -$2.37M | ﹤0.01% | 2023 |
|
|
2020
Q2 | $12.6M | Buy |
38,300
+9,900
| +35% | +$2.87M | ﹤0.01% | 1970 |
|
|
2020
Q1 | $6.88M | Buy |
28,400
+900
| +3% | +$235K | ﹤0.01% | 2308 |
|
|
2019
Q4 | $7.18M | Buy |
27,500
+6,300
| +30% | +$1.66M | ﹤0.01% | 2605 |
|
|
2019
Q3 | $5.76M | Sell |
21,200
-10,300
| -33% | -$2.87M | ﹤0.01% | 2913 |
|
|
2019
Q2 | $8.67M | Buy |
31,500
+2,400
| +8% | +$591K | ﹤0.01% | 2350 |
|
|
2019
Q1 | $6.51M | Sell |
29,100
-8,500
| -23% | -$1.75M | ﹤0.01% | 2624 |
|
|
2018
Q4 | $6.99M | Buy |
37,600
+12,500
| +50% | +$2.56M | ﹤0.01% | 2324 |
|
|
2018
Q3 | $6.27M | Buy |
25,100
+6,800
| +37% | +$1.65M | ﹤0.01% | 2697 |
|
|
2018
Q2 | $3.99M | Buy |
18,300
+8,500
| +87% | +$1.75M | ﹤0.01% | 3078 |
|
|
2018
Q1 | $1.88M | Buy |
9,800
+2,500
| +34% | +$461K | ﹤0.01% | 3829 |
|
|
2017
Q4 | $1.14M | Sell |
7,300
-5,300
| -42% | -$834K | ﹤0.01% | 4475 |
|
|
2017
Q3 | $1.96M | Sell |
12,600
-1,200
| -9% | -$190K | ﹤0.01% | 3434 |
|
|
2017
Q2 | $2.23M | Buy |
13,800
+2,400
| +21% | +$390K | ﹤0.01% | 3041 |
|
|
2017
Q1 | $1.76M | Buy |
11,400
+5,100
| +81% | +$703K | ﹤0.01% | 3206 |
|
|
2016
Q4 | $739K | Sell |
6,300
-6,400
| -50% | -$730K | ﹤0.01% | 4295 |
|
|
2016
Q3 | $1.43M | Buy |
+12,700
| New | +$1.34M | ﹤0.01% | 3384 |
|
Other funds holding IDXX
VCM
VPM
Citadel Advisors's IDXX Position: Q1 2026 in Review
Citadel Advisors increased its Idexx Laboratories (IDXX) stake by 391% in Q1 2026, buying an estimated $44.7M and bringing the position to 87,566 shares worth $49.2M. The position accounts for 0.01% of the portfolio, ranked #1381.
Citadel Advisors first reported a position in IDXX in Q2 2013 and has held it in 47 quarters since. The position peaked at $356M in Q1 2023. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Citadel Advisors held 87,566 shares of Idexx Laboratories worth $49.2M as of Q1 2026.
- Citadel Advisors bought 69,723 Idexx Laboratories shares in Q1 2026, an estimated $44.7M.
- Idexx Laboratories made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1381 holding.
- Citadel Advisors first reported a position in Idexx Laboratories in Q2 2013 and has held it in 47 quarters since.
- Citadel Advisors's Idexx Laboratories position peaked at $356M in Q1 2023.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.